Carol Schmidt, MD
Family Medicine · Melbourne, FLNPI 1609878883
Payments from drug & device makers
Across 221 payments — averaging $41.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Novo Nordisk$869
- Lilly USA, LLC$779
- Amgen$710
- Amarin Pharma, Inc.$414
- GSK$296
- plus $2K from 23 others
What the payments were for
- Food & beverage$9,169100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 66 | $4,210 |
| Novo Nordisk | 24 | $869 |
| Lilly USA, LLC | 16 | $779 |
| Amgen | 12 | $710 |
| Amarin Pharma, Inc. | 25 | $414 |
| GSK | 11 | $296 |
| Abbott | 8 | $270 |
| Merck | 13 | $208 |
| Astellas Pharma US Inc | 6 | $194 |
| Idorsia Pharmaceuticals US Inc | 5 | $148 |
| Pfizer | 2 | $139 |
| Corcept Therapeutics | 3 | $133 |
| Radius Health, Inc. | 1 | $124 |
| Biohaven Pharmaceuticals, Inc. | 3 | $117 |
| Teva Pharmaceuticals USA, Inc. | 2 | $115 |
| Novartis | 4 | $80 |
| Sanofi Pasteur Inc. | 4 | $70 |
| Gilead | 3 | $44 |
| Esperion Therapeutics, Inc. | 1 | $43 |
| Viiv Healthcare Company | 2 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| Phadia US Inc. | 1 | $24 |
| Avvisto Therapeutics, LLC | 1 | $23 |
| AbbVie | 1 | $18 |
| Almatica Pharma LLC | 1 | $17 |
| Grifols USA, LLC | 1 | $17 |
| Seqirus USA Inc | 1 | $16 |
| Shire North American Group Inc | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,181 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone Propionate | 21 | $507 |
| Levothyroxine Sodium | 21 | $382 |
| Celecoxib | 14 | $346 |
| Rosuvastatin Calcium | 44 | $316 |
| Metoprolol Succinate | 20 | $307 |
| Famotidine | 11 | $186 |
| Atorvastatin Calcium | 18 | $94 |
| Lisinopril | 12 | $49 |
| Alendronate Sodium | 11 | $45 |
| Amlodipine Besylate | 17 | $40 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Melbourne
- Christopher GallowayMelbourne$15.6M
- Murray KimmelMelbourne$7.9M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.